HIV DART 2018 – Presentations


Tuesday 27 November 2018

 Workshop Opening
Chairs: Charles Boucher & Raymond F. Schinazi
 Opening remarks and presentation of Gertrude Elion
Distinguished Lecturer Award
(Not yet available)
Raymond Schinazi, PhD, DSc - Emory University, United States
 Presentation of Gertrude Elion Distinguished Lecturer Award recipient
Rowena Johnston, PhD - amfAR, United States
 Gertrude Elion Distinguished Lecturer Award Lecture:
Innovating to impact global health
(Not yet available)
Paul Stoffels, MD - Johnson and Johnson, United States
 Session 1 - Cure Session 1: Basic science and pre-clinical developments
Chairs: Steven Deeks & Rowena Johnston
 State-of-the-Art Lecture: Molecular basis for HIV latency
Jonathan Karn, PhD - Case Western Reserve University, United States
 Understanding barriers to HIV cure
Robert Siliciano, MD, PhD - Johns Hopkins University, United States
 HIV reservoir dynamics: Implications for HIV latency establishment and reversal
Deanna Kulpa, PhD - Emory University, United States
 Session 2 - Cure Session 2: Clinical implementation
Chairs: Raymond F. Schinazi & Jonathan Karn
 State-of-the-Art Lecture: Harnessing the immune system
to eliminate and/or control HIV
Steven Deeks, MD - University of California San Francisco, United States
 Baricitinib reverses HIV associated neurocognitive disorders
and reservoir seeding in a SCID mouse model
Christina Gavegnano, PhD - Emory University, United States
 Potential for HIV cure by stem cell transplantation (IciStem)
Monique Nijhuis, PhD - University Medical Center Utrecht, The Netherlands
 Oral Abstract Session 1: New small molecule inhibitors and drug resistance
Chairs: Eddy Arnold & Deanna Kulpa
 The inhibitor of apoptosis proteins antagonist DEBIO 1143 is a promising HIV-1 latency reversal agent
(Not yet available)
Philippe Gallay, PhD - The Scripps Research Institute, United States
 Oral ABX464 has a dose dependent reduction in the HIV-1 DNA reservoir in CD4+ Peripheral Blood T Cells
Jean-Marc Steens, MD - Abivax, France
 Differential detection of M184V/I between plasma historical HIV genotypes and proviral DNA from PBMCs
Nicolas Margot, MA - Gilead Sciences Inc., United States


Wednesday 28 November 2018

 Presentation of Barry-Wainberg DART Achievement Award
Charles Boucher, PhD - Erasmus MC, the Netherlands
 Barry-Wainberg DART Achievement Award Lecture: How AIDS research has evolved to many other fields
Bonaventura Clotet, MD, PhD - Universitat Autònoma de Barcelona, Spain
 Session 3 - New drugs and improved formulations
Chairs: Leor S. Weinberger & Monique Nijhuis
 State-of-the-Art Lecture: Rational design of doravirine (DOR): From bench to patients
Daria Hazuda, PhD - Merck, United States
 Injectable ART: Advantages and disadvantages
Michael Saag, MD - University of Alabama, United States
 Session 4 - Cutting edge developments in therapeutic and curative strategies
Chairs: Mikaela Müller-Trutwin & Daria Hazuda
 State-of-the-Art Lecture: Trispecific Antibodies for the Prevention and Treatment of HIV Infection and Cancer
(Not yet available)
Gary Nabel, MD - Sanofi, France
 Long-term virologic suppression following AAV delivery of anti-HIV monoclonal antibodies
(Not yet available)
Ron Desrosiers, PhD - University of Miami, United States
 A post-transcriptional feedback mechanism for noise suppression and fate stabilization
Leor Weinberger, PhD - University of California - San Francisco, United States
 Session 5 - Inflammation, NeuroAIDS, aging, and immunotherapy
Chairs: Ron Desrosiers & Charles Flexner
 Inflammation, HIV and aging
Savita Pahwa, MD - University of Miami, United States
 Hispanic/Latino longitudinal cohort of HIV-seropositive women and neurological complications
(Not yet available)
Loyda Melendez, PhD - University of Puerto Rico, Puerto Rico
 Oral Abstract Session 2: HIV treatment and clinical trial outcomes
Chairs: Michael Saag & Robert Siliciano
 Prevalence of neuropsychiatric conditions among HIV positive compared to HIV negative commercially insured individuals in 2017
Joshua Cohen, PhD - Tufts University, United States
 Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in a rapid initiation model of care for HIV-1 infection: Week 24 interim analysis of the DIAMOND study
Keith Dunn, PharmD, BCPS, AAHIVE - Janssen Scientific Affairs, LLC, France
 Initial viral load decline and response rates by baseline viral load strata with dolutegravir plus lamivudine versus dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: Pooled results from the GEMINI studies
Michael Aboud - GlaxoSmithKline, United Kingdom

Thursday 29 November 2018

 Session 6 Emerging viruses: Epidemiology, diagnosis
Chairs: Mauro Teixeira & Mehul Suthar
 State-of-the-Art Lecture: Post-natal Zika virus infections
(Not yet available)
Ann Chahroudi, MD, PhD - Emory University, United States
 Oral Abstract Session 3: Therapeutics and novel study models
Chairs: Matthias Götte & Ladislau Kovari
 Rhesus macaque model of SIV/SHIV-Zika co-infection
Siddappa Byrareddy, PhD - University of Nebraska Medical Center, United States
 Session 7 Emerging viruses: treatment
Chairs: Ann Chahroudi & David Watkins
 Development of protease inhibitors against norovirus and other emerging viruses
Ladislau Kovari, PhD - Wayne State University, United States